From Biomarker Measurement to Clinical Utility: Lessons From Six Established Biomarkers

Biomarkers are increasingly used to support diagnosis, risk stratification, therapeutic selection, monitoring, and prognosis.Advances in high-sensitivity assays, molecular diagnostics, multi-omics, and artificial intelligence have accelerated biomarker discovery, but improved measurement does not necessarily translate into improved care.A biomarker may be analytically robust and strongly associated with disease while adding little to clinical decision-making.This narrative review examines the progression from analytical validity and clinical association to incremental value, actionability, clinical utility, and net clinical benefit.Six familiar biomarkers were selected as illustrative case studies because each represents a different point at which biomarker translation may succeed or fail.D-dimer shows how clinical context and pretest probability can transform a nonspecific marker into an efficient diagnostic tool.Procalcitonin demonstrates that utility often depends on the management algorithm attached to the result.Highsensitivity cardiac troponin illustrates both the benefits and the interpretive burden created by detecting smaller degrees of myocardial injury.Point-of-care C-reactive protein testing shows that clinical value does not require technological novelty.Conversely, N-terminal pro-B-type natriuretic peptide demonstrates that strong prognostic value does not necessarily validate biomarker-targeted therapy, while cancer antigen 125 screening for ovarian cancer shows that earlier detection and stage shift cannot be assumed to improve mortality and may expose patients to downstream harm.Taken together, these examples suggest that the clinically relevant unit is not the biomarker in isolation but the biomarker-enabled decision pathway.Biomarker research should therefore move beyond association and discrimination toward evidence that testing changes meaningful decisions and that the resulting strategy provides greater benefit than harm compared with current care.